Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12751319 | 0.89 | BRD4 (0.45) | BRD4SLC22A1OPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL16086032 | 0.88 | BRD4 (0.37) | BRD4SLC22A1OPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL16086031 | 0.88 | BRD4 (0.37) | BRD4SLC22A1OPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL17616814 | 0.81 | SCN9A (0.34) | — | |
| SCHEMBL472066 | 0.80 | CYP3A4 (0.33) | SMN1; SMN2KDM4E | |
| SCHEMBL16471455 | 0.80 | BRD4 (0.40) | BRD4SLC22A1OPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL13755065 | 0.80 | SLC22A1 (0.39) | SLC22A1OPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL472139 | 0.79 | NPSR1 (0.34) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27910816 | 0.79 | BRD4 (0.42) | BRD4SLC22A1OPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL2289941 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104822376-A | 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as ROR γ T inhibitors and uses thereof | MERCK SHARP & DOHME | 2015-08-05 | — | — | CN | disclosed |
| US-8664414-B2 | Process for producing epoxy compound | SHOWA DENKO K.K. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8466303-B2 | Process for production of epoxy compound | SHOWA DENKO K.K. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120029217-A1 | PROCESS FOR PRODUCING EPOXY COMPOUND | SHOWA DENKO K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2412712-A1 | METHOD FOR PRODUCING EPOXY COMPOUND | Showa Denko K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20110009652-A1 | PROCESS FOR PRODUCTION OF EPOXY COMPOUND | SHOWA DENKO KK (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2261219-A1 | PROCESS FOR PRODUCTION OF EPOXY COMPOUND | Showa Denko K.K. (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029217-A1 | PROCESS FOR PRODUCING EPOXY COMPOUND | NOX4, NOX5, NOXO1 | BRD4 672/4885SLC22A1 4363/4885OPRM1 597/4885 |
| US-20110009652-A1 | PROCESS FOR PRODUCTION OF EPOXY COMPOUND | DUOX2, EPX, DUOX1 | BRD4 2061/4885SLC22A1 4837/4885OPRM1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.